Catheter-directed therapy (CDT) is being used to treat pulmonary embolism (PE) more and more by healthcare providers, according to new research published in the Journal of Vascular and Interventional Radiology.

The FDA has cleared Current Health’s wireless wearable remote patient monitoring (RPM) platform for chronically ill individuals, allowing care teams to track their patients’ health in real-time and act proactively when something looks off.

MicroRNAs could be key to treating heart failure, according to a study out of Boston Children’s Hospital and Zhejiang University School of Medicine in China.

The University of Southern California will lose its cardiology fellowship accreditation after more than a year of unrest within the medical school, the Los Angeles Times reported April 25.

A national effort to recall carcinogen-tainted batches of the popular blood pressure drug losartan has once again expanded, growing to include one lot of the medication distributed by Legacy Pharmaceutical Packaging, LLC.

The Radiological Society of North America (RSNA) on April 25 launched the first issue of its newest online journal, Radiology: Cardiothoracic Imaging.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Guerbet, a medical imaging company out of Villepinte, France, this week announced it received CE mark approval for its SeQure and DraKon devices, two microcatheters that facilitate the intra-arterial delivery of therapies and embolic materials to peripheral vessels.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.